Literature DB >> 15466207

Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells.

Alessia Montagnoli1, Pierluigi Tenca, Francesco Sola, Daniela Carpani, Deborah Brotherton, Clara Albanese, Corrado Santocanale.   

Abstract

Cdc7 is an evolutionarily conserved kinase that regulates S phase by promoting replication origin activation. Down-regulation of Cdc7 by small interfering RNA in a variety of tumor cell lines causes an abortive S phase, leading to cell death by either p53-independent apoptosis or aberrant mitosis. Unlike replication fork blockade, Cdc7-depleted tumor cells do not elicit a robust checkpoint response; thus, inhibitory signals preventing additional cell cycle progression are not generated. In normal fibroblasts, however, a p53-dependent pathway actively prevents progression through a lethal S phase in the absence of sufficient Cdc7 kinase. We show that in this experimental system, p53 is required for the lasting maintenance of this checkpoint and for cell viability. With this work we reveal and begin to characterize a novel mechanism that regulates DNA synthesis in human cells, and we suggest that inhibition of Cdc7 kinase represents a promising approach for the development of a new generation of anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466207     DOI: 10.1158/0008-5472.CAN-04-1547

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

1.  Chk1 promotes replication fork progression by controlling replication initiation.

Authors:  Eva Petermann; Mick Woodcock; Thomas Helleday
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

2.  Quantitative proteomics reveals a "poised quiescence" cellular state after triggering the DNA replication origin activation checkpoint.

Authors:  Claire Mulvey; Slavica Tudzarova; Mark Crawford; Gareth H Williams; Kai Stoeber; Jasminka Godovac-Zimmermann
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

Review 3.  DNA replication licensing control and rereplication prevention.

Authors:  Chonghua Li; Jianping Jin
Journal:  Protein Cell       Date:  2010-02-23       Impact factor: 14.870

4.  Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.

Authors:  Sara Rodriguez-Acebes; Ian Proctor; Marco Loddo; Alex Wollenschlaeger; Mohammed Rashid; Mary Falzon; A Toby Prevost; Richard Sainsbury; Kai Stoeber; Gareth H Williams
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

5.  The functional role of Cdc6 in S-G2/M in mammalian cells.

Authors:  Eric Lau; Changjun Zhu; Robert T Abraham; Wei Jiang
Journal:  EMBO Rep       Date:  2006-01-27       Impact factor: 8.807

Review 6.  Cell cycle regulation of DNA replication.

Authors:  R A Sclafani; T M Holzen
Journal:  Annu Rev Genet       Date:  2007       Impact factor: 16.830

7.  Expression of huCdc7 in colorectal cancer.

Authors:  Hai-Jun Chen; Zhen Zhu; Xue-Lin Wang; Quan-Lin Feng; Qing Wu; Zheng-Ping Xu; Jiang Wu; Xiao-Feng Yu; Hong-Liang Qian; Qi Lu
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

Review 8.  Exploiting replicative stress to treat cancer.

Authors:  Matthias Dobbelstein; Claus Storgaard Sørensen
Journal:  Nat Rev Drug Discov       Date:  2015-05-08       Impact factor: 84.694

9.  Nuclear accumulation of the papillomavirus E1 helicase blocks S-phase progression and triggers an ATM-dependent DNA damage response.

Authors:  Amélie Fradet-Turcotte; Fanny Bergeron-Labrecque; Cary A Moody; Michaël Lehoux; Laimonis A Laimins; Jacques Archambault
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

10.  Drug design with Cdc7 kinase: a potential novel cancer therapy target.

Authors:  Masaaki Sawa; Hisao Masai
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.